MRSN - צמיחת הכנסות ב-12 חודשים נגררים mersana.com

Mersana Therapeutics (MRSN) is developing breakthrough Dolaflexin ADC drugs to combat breast and ovarian cancers, supported by large-scale R&D investments. The rolling annual sales growth trend visualizes current dynamics, where the value of -4.70 reflects the metric's balance. The implementation of AI modeling is accelerating drug synthesis, while the development of a lung therapy pipeline is improving patient comfort during treatment.
פילוחי נתונים אנליטיים מרוכזים עבור mersana.com (MRSN)

This metric is calculated as the percentage ratio of current trailing twelve-month (TTM) revenue to the same period last year. This metric measures business scaling rates, neutralizing quarterly volatility through daily recalculations. For Mersana Therapeutics (MRSN), this is a critical marker of the ability to restore commercial potential following clinical trial failures. Amid intense competition in oncology, the TTM revenue growth trajectory compared to the previous year reflects the actual viability of the platform.